What is Sildenafil Citrate? A Pharmaceutical Export Overview
Sildenafil Citrate is a phosphodiesterase type 5 (PDE5) inhibitor originally developed as a cardiovascular medication. During clinical trials in the early 1990s, researchers discovered its pronounced effect on erectile function — a finding that redirected its development entirely. The FDA approved Sildenafil for erectile dysfunction in 1998, making it one of the fastest approvals of that era.
The mechanism involves inhibition of the PDE5 enzyme in corpus cavernosum smooth muscle, allowing cyclic GMP to accumulate and promote vasodilation in response to sexual stimulation. The same mechanism — acting on pulmonary vascular smooth muscle — underpins its second approved indication: pulmonary arterial hypertension (PAH).
Since the original Pfizer patent expired across most markets between 2012 and 2020, generic Sildenafil has become one of the highest-volume pharmaceutical molecules in international trade. India is the world's largest manufacturer of generic Sildenafil for export, with dozens of WHO-GMP certified facilities producing compliant formulations at competitive prices.
For pharmaceutical buyers, key considerations include: bioequivalence documentation (essential for regulated market entry), available strengths (25mg, 50mg, 100mg), formulation type (standard tablets, chewable, oral jelly), and pack configurations. Indian manufacturers can supply all of these formats with full Certificate of Analysis (COA) and WHO-GMP documentation.